General Information of DTT (ID: TT4YWTO)

DTT Name Histone deacetylase 3 (HDAC3) DTT Info
UniProt ID
HDAC3_HUMAN
Gene Name HDAC3

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Clinical Trial Drug(s)
1 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
CHR-3996 DMIXPNG Lymphoma 2A80-2A86 Phase 1/2 [1]
------------------------------------------------------------------------------------
16 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diaryl amine derivative 4 DMZL6AX N. A. N. A. Patented [2]
PMID29671355-Compound-11 DMNKABH N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [3]
PMID29671355-Compound-55 DMJV1SY N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-57 DM57N3Y N. A. N. A. Patented [3]
PMID29671355-Compound-59 DM2F0CQ N. A. N. A. Patented [3]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [3]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-8 DM7YQJK N. A. N. A. Patented [3]
PMID29671355-Compound-9 DMXL96M N. A. N. A. Patented [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Patented Agent(s)
2 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
droxinostat DM5IA9W Discovery agent N.A. Investigative [4]
RGFP966 DME9T0A Discovery agent N.A. Investigative [5]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
2 Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236.
3 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
4 Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56.
5 HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52.